IPOs and Secondaries

IPOs and Secondaries Articles

Clearside Biomedical has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Depending on how you count these things, the month of March now has two or three initial public offerings (IPOs) to its credit.
Hutchinson China MediTech will offer more than 7 million American depositary shares at $13.50 apiece in and IPO valued at up to more than $116 million.
Global Water Resources has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Red Rocks Resorts has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Aeglea BioTherapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Senseonics Holdings has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing for...
PSAV has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Blank-check company KLR Energy Acquisition Corp. (NASDAQ: KLREU) completed its initial public offering (IPO) last Friday, the first successful IPO in the month of March. An Israel-based firm that...
Blank-check company KLR Energy Acquisition completed an IPO Friday morning, raising $80 million on the sale of 8 million units at a per unit price of $10.
Corvus Pharmaceuticals expects to price more than 4 million shares in the range of $15 to $17 apiece in an initial public offering valued up to nearly $92 million.
Audentes Therapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
The long-term exit strategy for more than half of U.S. technology and life sciences startups is to be acquired, according to Silicon Valley Bank.
Spring Bank Pharmaceuticals expects to price more than 2.8 million shares in the range of $13 to $15 per share in an IPO valued at up to more than $49 million.
Wingstop plans to offer more than 5 million shares in a secondary offering valued at up to more than $158 million.